NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,381−0.16%BTC$76,473+0.42%VIX15.44−12.82%live tape · as of 21:00 UTC
The Screen · Healthcare · Health Information Services
Teladoc Health, Inc.
TDOC · the NYSE · USD · Market cap $1.2B · 4,648 employees
Teladoc Health, Inc.
FAIL · Does not pass the screen
6.43 USD
At the last full screen 2026-09-16
Screened 2026-09-16 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Teladoc Health, Inc. holds its Accumulation at $6.43. The statistical read favours the buyers, held for 29 days.
As held on the ledger · 2026-09-16
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 29 days
Price at the screen
$6.43
Valuation
N/A trailing · -8.19 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.13
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
36.39%
Below 33%
Interest-bearing debt is 36.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
34.07%
Below 49%
Money owed to the company is 34.1% of assets, under the 49% limit.
Pass
Revenue purity
1.45%
Below 5%
Only 1.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. A 16.6% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus None. The average target sits +17% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Virtual Doctor Visits Fail to Heal Losses
A patient opens an app expecting quick care from anywhere yet the business behind it keeps shrinking. Revenue fell 2 percent last year while losses left profit margins at minus 7 percent and return on equity at minus 12 percent. The shares sit at 9.43 dollars against a fair value of just 7 dollars, so the market already prices in recovery that the numbers do not support.
We pass for straightforward reasons. Forward earnings sit at a negative 14.6 times with no growth in sight and an unknown competitive edge. Nineteen analysts call the stock a hold with a median target matching our own fair value, leaving no margin of safety and no reason to step in.
Currency moves or regulation could worsen the picture, yet the core issue remains simple: a business burning cash in a crowded field rarely rewards patience when earnings stay negative. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TDOC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-14Markdown · changed$6.36-5.2%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (21 analysts) rates it buy, with a mean price target of $7.
2026-08-14Distribution · changed$6.71-8.6%Entry 4
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (21 analysts) rates it buy, with a mean price target of $7.
2026-07-18Accumulation$7.34+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (21 analysts) rates it buy, with a mean price target of $7.
2026-07-03Accumulation$7.34+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$7.34Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
